Background: To investigate the effects of levosimendan on right ventricular (RV) function in patients with acute decompensated heart failure (ADHF).
Methods: Patients with ADHF admitted from January 2017 to October 2017 were enrolled in this study. The patients were randomized to receive 24-h intravenous levosimendan or placebo. Echocardiographic examinations were performed and the parameters were compared. Epidemiological data were recorded and compared before and after treatment. Major adverse cardiac events during hospitalization and during 1-month follow-up were compared.
Results: The baseline characteristics were comparable. After 24-h infusion of levosimendan and placebo, the left ventricular ejection fraction and S' were significantly increased in the levosimendan group compared with the control group (both p < 0.05). The E value in the levosimendan group significantly decreased (75.38 ± 8.32 vs. 88.21 ± 10.36, p < 0.0001), and E/e' significantly increased in the control group (19.61 ± 6.52 vs. 27.58 ± 8.22, p < 0.0001). The levels of right ventricular fractional area change (24 ± 3 vs. 20 ± 2, p < 0.0001) and tricuspid annular plane systolic excursion (1.56 ± 0.36 vs. 1.38 ± 0.21, p < 0.0001) were significantly higher in the levosimendan group than in the control group. After treatment, the values of systolic pulmonary artery pressure (SPAP) decreased in both groups (both p < 0.05), and the value of SPAP in the levosimendan group was lower than that in the control group (47.22 ± 5.6 vs. 55.85 ± 7.41, p < 0.0001). After 1-month follow-up, there was no significance in readmissions due to recurrent heart failure.
Conclusions: Levosimendan seems to provide more beneficial effects among patients with ADHF to improve RV function, along with a decrease in pulmonary pressure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859094 | PMC |
| http://dx.doi.org/10.6515/ACS.201911_35(6).20190327A | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of Levosimendan on Low Cardiac Output Syndrome After Pericardiectomy.
Ther Clin Risk Manag
December 2024
Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People's Republic of China.
Background: Low cardiac output syndrome (LCOS) after pericardiectomy is associated with high morbidity and mortality. This study aimed to assess the effect of levosimendan on postoperative LCOS in the patients with constrictive pericarditis.
Methods: Patients were retrospectively enrolled, and those receiving the treatment of levosimendan were assigned in the LEVO (+) group, and others were in the LEVO (-) group.
Prophylactic use of inotropic agents for the prevention of low cardiac output syndrome and mortality in adults undergoing cardiac surgery.
Cochrane Database Syst Rev
November 2024
Department of Anaesthesiology and Surgical Intensive Care, University Medicine Halle, Halle (Saale), Germany.
Background: As the burden of cardiovascular disease grows, so does the number of cardiac surgeries. Surgery is increasingly performed on older people with comorbidities who are at higher risk of developing perioperative complications such as low cardiac output state (LCOS). Surgery-associated LCOS represents a serious pathology responsible for substantial morbidity and mortality.
View Article and Find Full Text PDFLevosimendan in Patients with Low Cardiac Output Syndrome After Cardiac Surgery: A Substudy of the Multicenter Randomized CHEETAH Trial.
J Cardiothorac Vasc Anesth
October 2024
Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Objective: To test the hypothesis that levosimendan administration in patients with low cardiac output syndrome after cardiac surgery is associated with improved long-term (5-year follow-up) outcomes.
Design: Single-center subanalysis of the multicenter randomized CHEETAH trial.
Setting: Cardiac surgery department of a tertiary hospital.
Levosimendan in Patients with Cardiogenic Shock Refractory to Dobutamine Weaning.
Am J Cardiovasc Drugs
October 2024
ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris-Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
Background: This study examines the effects of levosimendan in patients refractory to dobutamine weaning.
Methods: This retrospective study included patients with cardiogenic shock refractory to dobutamine weaning failure admitted between 2010 and 2022. Patients treated with another type of dobutamine alone were compared with those treated with levosimendan in combination with dobutamine.
Efficacy and safety of levosimendan in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: The LEVOCEST trial.
Catheter Cardiovasc Interv
December 2024
Department of Interventional Cardiology, University Hospital of the Canary Islands, La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain.
Article Synopsis
- Primary angioplasty is the standard treatment for ST-segment elevation myocardial infarction (STEMI), but it can cause additional cell damage, which levosimendan may help prevent.
- In a study, patients received either levosimendan or a placebo after angioplasty, and their heart damage was assessed over 6 months.
- Results showed that those treated with levosimendan had a significant reduction in infarct size compared to the placebo group, confirming its safety and effectiveness in this context.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!